{{Rsnum
|rsid=351855
|Gene=FGFR4
|Chromosome=5
|position=177093242
|Orientation=minus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.303
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FGFR4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 43.1 | 53.4 | 3.4
| HCB | 24.4 | 58.5 | 17.1
| JPT | 30.8 | 53.8 | 15.4
| YRI | 77.6 | 22.4 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 24.4 | 58.5 | 17.1
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs351855]], a SNP in the fibroblast growth factor receptor 4 ([[FGFR4]]) gene, is also known as the Gly388Arg variant. The [[rs351855]](T) allele encodes the risk (Arg) allele.

The Arg form of this SNP is likely to cause a harder to treat version of node-positive [[breast cancer]], including reducing the efficacy of [[Herceptin]], based on a study of 372 patients.{{PMID|16822847}}

A study of ~500 Japanese [[prostate cancer]] patients found that individuals with a [[rs351855]](T;T) genotype had a 2.2- and 1.9-fold increased risk of [[prostate cancer]] and benign prostate hyperplasia (BPH), and a 1.8-fold increased risk of metastatic prostate cancer compared to the (C;C) genotype.{{PMID|18756523}}

A meta-analysis published in 2011, surveying a total of 2,618 cases of [[prostate cancer]], concluded that the odds ratio per [[rs351855]](T) allele was 1.17 (CI: 1.07 - 1.29), and that when stratified by race, Caucasians and Asians were at highest risk.{{PMID|21349172|OA=1
}}

{{PMID|18762813|OA=1
}} ~1500 prostate cancer patients showed only a weak association between [[rs351855]] and prostate-cancer specific mortality, and no evidence associating it with prostate cancer risk, disease aggressiveness, Gleason score, or stage.

{{omim
|desc=CANCER PROGRESSION AND TUMOR CELL MOTILITY
|id=134935
|rsnum=351855
|variant=0001
}}

{{PharmGKB
|RSID=rs351855
|Name_s=FGFR4:GLY388ARG; FGFR4:Arg388
|Gene_s=FGFR4
|Feature=
|Evidence=PubMed ID:11830541; PubMed ID:15197773; PubMed ID:16822847; PubMed ID:17084840; PubMed ID:18487077
|Annotation=This variant is associated with cancer progression and tumor cell motility. Patients carrying arg388 allele was associated with metastasis and poor prognosis in breast cancer and in colon cancer as well as poor clinical outcome for head and neck squamous cell carcinoma. possible association with sensitivity to cisplatin. It is associated with resistence to adjuvent systemic therapy in primary breast cancer.
|Drugs=cisplatin; cyclophosphamide; fluorouracil; methotrexate; tamoxifen
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA161822200
}}

{{PMID Auto
|PMID=21412156
|Title=Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor
}}

{{PMID Auto
|PMID=21656577
|Title=Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma
}}

{{PMID Auto
|PMID=22271411
|Title=Pharmacogenetics of the Effects of Colesevelam on Colonic Transit in Irritable Bowel Syndrome with Diarrhea.
|OA=1
}}

{{PMID Auto
|PMID=22313031
|Title=Fibroblast Growth Factor Receptor 4 Polymorphisms and Susceptibility to Coronary Artery Disease.
|OA=1
}}

{{PMID Auto
|PMID=22696188
|Title=Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study
}}

{{ClinVar
|rsid=351855
|Reversed=1
|FwdREF=C
|FwdALT=T
|REF=G
|ALT=A
|RSPOS=176520243
|CHROM=5
|GMAF=0.3027
|dbSNPBuildID=79
|SSR=0
|SAO=1
|VP=0x05016800000015051f110100
|GENEINFO=FGFR4:2264
|GENE_NAME=FGFR4
|GENE_ID=2264
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000005.9:g.176520243G>A
|CLNORIGIN=1
|CLNSIG=5
|Tags=RV;PM;PMC;SLO;VLD;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.697; 0.303
|CLNACC=RCV000017723.26
|CLNDBN=Cancer progression and tumor cell motility
|CLNSRC=OMIM Allelic Variant
|CLNSRCID=134935.0001
|COMMON=1
|Disease=Cancer progression and tumor cell motility
}}

{{PMID Auto
|PMID=19379518
|Title=Development of a fingerprinting panel using medically relevant polymorphisms.
|OA=1
}}

{{PMID Auto
|PMID=19500394
|Title=Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study.
|OA=1
}}

{{PMID Auto
|PMID=20565774
|Title=Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.
|OA=1
}}

{{PMID Auto
|PMID=21396369
|Title=A Klothobeta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.
|OA=1
}}

{{GET Evidence
|gene=FGFR4
|aa_change=Gly388Arg
|aa_change_short=G388R
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs351855
|overall_frequency_n=2590
|overall_frequency_d=10750
|overall_frequency=0.24093
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=27
|n_articles=0
|n_articles_annotated=0
|qualityscore_in_silico=5
|qualitycomment_in_silico=Y
|in_omim=Y
|in_pharmgkb=Y
|pph2_score=0.481
|nblosum100=6
|autoscore=2
|webscore=N
|summary_short=Possible association with sensitivity to cisplatin; poor outcome with cyclophosphamide, fluoruracil, methotextrate and tamoxifen.
}}

{{PMID Auto
|PMID=23206452
|Title=Association between Fibroblast Growth Factor Receptor 4 Gly388Arg Polymorphism and Ischaemic Stroke
}}

{{PMID Auto
|PMID=24381107
|Title=Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma
}}

{{PMID Auto
|PMID=23524567
|Title=FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}